CLL Advocates NZ - Latest News [Page 1]
Funding Of Chronic Lymphocytic Leukaemia With Ibrutinib + Venetoclax And Obinutuzumab + Venetoclax
Wednesday, 18 February 2026, 1:51 pm | CLL Advocates NZ
CLL Advocates NZ will continue to fight for better treatments for CLL patients. CLL is one of the most common blood cancers, with an increasing incidence in the aging population. More >>
